Approximately 100 hospitalized volunteers will be assigned to each study arm with each of the study sites testing no more than three investigational treatments at once. Remdesivir has demonstrated clinical benefit for patients with severe COVID-19 requiring supplemental oxygen and is considered standard of care for hospitalized COVID-19 patients. Lenzilumab is currently being tested separately in a phase 3 COVID-19 study and in a phase 1b/2 study as sequenced therapy with CAR-T treatments. In the ACTIV-5/BET study, volunteers assigned to receive risankizumab will be administered a single intravenous dose on day one of the study. For more information about the ACTIV-5/BET trial, please visit ClinicalTrials.gov using the identifier NCT04583969.
At Wellness Axis we want to encourage habits of wellness, Increase awareness of factors and resources contributing to well-being, Inspire and empower individuals to take responsibility for their own health, and to support a sense of community. Wellness can be thought of as the quality or state of being in good health.